Nasdaq 100 Stocks SEC Filings — June 01, 2026

01-06-2026

AITX announced that its subsidiary RAD scaled production, with Q1 FY27 hardware device shipments exceeding 100 units. The company issued a press release on June 1, 2026, highlighting this milestone. No financial figures or period-over-period comparisons were provided in the filing.

• · The press release is titled 'AITX’s RAD Scales Production as Q1 FY27 Shipments Exceed 100 Hardware Devices'.
• · The filing is an 8-K under Items 8.01 and 9.01, and the press release is attached as Exhibit 99.1.
• · The company's principal executive offices are located at 10800 Galaxie Avenue, Ferndale, MI 48220.

01-06-2026

Liberty Star Uranium & Metals Corp. entered into a Securities Purchase Agreement with Monroe Street Capital Partners LP on May 18, 2026, issuing a convertible promissory note with a principal amount of $123,200, including a 10% original issue discount. The note bears 8% interest, matures in one year, and is convertible into common stock. This creates a direct financial obligation for the company.

• · The note matures in one year from the date of the agreement (May 18, 2026).
• · The note is convertible into shares of common stock.
• · The Securities Purchase Agreement is dated April 15, 2026, but the note was issued effective May 26, 2026.
• · The filing includes exhibits: Convertible Promissory Note (Exhibit 3.83) and Securities Purchase Agreement (Exhibit 3.84).

01-06-2026

Diana Shipping Inc. filed an amended Schedule 13D/A disclosing its tender offer to acquire all outstanding shares of Genco Shipping & Trading Ltd at $24.80 per share, now beneficially owning 6,264,548 shares (14.4% of class). The filing includes an open letter and video message urging Genco shareholders to elect Diana’s six independent director nominees at the June 18, 2026 annual meeting, while criticizing the Genco board for spending over $13 million on defensive advisors and failing to engage on the offer. However, the tender offer has not yet been accepted by the board, and Diana notes that Genco’s share price could revert to ~$18.00 (a ~30% discount to NAV) if no deal is completed.

• · Diana's offer represents ~1.0x NAV at cyclically high asset values, while comparable industry buyouts trade at ~0.80x NAV.
• · Genco had 43,577,051 common shares outstanding as of May 6, 2026.
• · The tender offer expires at 5:00 p.m. New York City time on June 26, 2026.
• · Genco's annual meeting is scheduled for June 18, 2026.
• · Diana has increased its offer three times (third proposal at $24.80).
• · John Wobensmith serves as both Chairman and CEO after adding the Chairman role in August 2025 as Diana was acquiring Genco shares.
• · A majority of Wobensmith's Genco stock was pledged as collateral for personal loans (since repaid).
• · Kathleen Haines was named co-defendant in three shareholder class action lawsuits alleging lack of independence while serving on the OSG America board.

01-06-2026

MoonLake Immunotherapeutics entered into a Master Commercial Supply Agreement and a Capacity Agreement with Vetter Pharma International GmbH on May 22, 2026, for manufacturing of pre-filled application systems. The agreements include binding capacity commitments with minimum and maximum quantities, and potential compensation obligations if MoonLake fails to meet commitments. No financial terms were disclosed.

• · The Vetter MCSA is a master agreement under which product-specific schedules will detail manufacturing services and pricing.
• · Either party may terminate the Vetter MCSA without cause upon 12 months' written notice.
• · Vetter may terminate if MoonLake undergoes a Change of Control to an acquirer not meeting specified criteria; MoonLake may terminate if Vetter is taken over by a competitor in dermatology/inflammatory diseases before end of 2029.
• · The Capacity Agreement requires MoonLake to provide aggregate demand forecasts, with annual demands for the initial term constituting a binding commitment (MoonLake Commitment).
• · MoonLake may be obligated to pay capacity compensation if it fails to order the Minimum Quantity or fails to provide purchase orders.

01-06-2026

Trilogy Metals Inc. announced an extension of the closing deadline for the previously announced US$35.6M strategic equity investment from the U.S. Department of War (DOW) to July 31, 2026. Key milestones have been completed, including the FOCI risk assessment and the DPA reauthorization, while definitive documentation is progressing. Concurrently, the Arctic Project achieved FAST-41 designation, ensuring a transparent federal permitting timetable, though the investment closing remains delayed, highlighting mixed progress.

• · FOCI risk assessment of Trilogy Metals has been completed by the U.S. Government, allowing finalization of definitive agreements.
• · U.S. Congress reauthorized the Defense Production Act, providing continued statutory foundation for the investment program.
• · The Arctic Project was officially accepted as a 'Covered Project' under FAST-41 on May 15, 2026, triggering statutory permitting timelines.
• · Ambler Metals is a 50/50 joint venture between Trilogy and South32, formed in December 2019.
• · The Arctic Project hosts one of the highest-grade undeveloped copper-zinc-lead-gold-silver deposits in North America.

01-06-2026

Weatherford International plc (NASDAQ: WFRD) announced a definitive agreement to acquire NCS Multistage Holdings, Inc. (NASDAQ: NCSM). Under the terms, NCS Multistage stockholders can elect to receive either 0.554 shares of Weatherford common stock or a combination of 0.239 shares and cash equivalent to 0.137 shares, with a blended equivalent of 0.463 shares per NCSM share and up to 19.99% of total equity consideration payable in cash. The transaction is expected to close in the second half of 2026 and is expected to be immediately accretive to adjusted free cash flow per share, with annual cost synergies of at least $15 million to be realized within 18 months of closing. However, the deal is subject to customary closing conditions and regulatory approvals, and no specific revenue or earnings growth targets for NCS Multistage were disclosed.

• · The transaction has been approved by the boards of both companies and the controlling stockholder of NCS Multistage, which owns more than 50% of its outstanding common stock.
• · NCS Multistage stockholders have an election to receive either 0.554 shares of Weatherford common stock or a combination of 0.239 shares plus cash equal to 0.137 shares of Weatherford common stock, subject to proration.
• · Weatherford expects to realize at least $15 million in annual run-rate cost synergies within 18 months of closing.
• · The deal is expected to be immediately accretive to adjusted free cash flow per share.
• · Weatherford and NCS Multistage will continue to operate as separate, independent companies until the transaction closes.

01-06-2026

Community Financial System, Inc. (CBU) announced the completion of its acquisition of ClearPoint Federal Bank & Trust by its subsidiary Community Bank, N.A. on June 1, 2026. ClearPoint is a national leader in trust administration for the death care industry with over $1.5 billion in assets under management and a historical three-year revenue CAGR of 9.7%. The transaction expands the wealth management services of Nottingham Financial Group and aligns with the company's strategic focus on durable, recurring income streams.

• · The acquisition was completed on June 1, 2026, as previously announced in an Agreement and Plan of Merger dated January 14, 2026.
• · The newly acquired business will operate as ClearPoint Trust, a division of Community Bank.
• · The press release announcing the closing is attached as Exhibit 99.1 to the 8-K filing.

01-06-2026

Sun Communities, Inc. (SUI) filed an 8-K on June 1, 2026, to furnish an investor presentation that will be made available to investors and posted on its website. The filing also discloses forward-looking risks related to the proposed sale of Park Holidays, including the ability to complete the sale on a timely basis, potential disruptions to operations, and the realization of anticipated benefits.

• · The investor presentation is furnished under Item 7.01 Regulation FD Disclosure and is not deemed 'filed' for SEC purposes.
• · The filing includes extensive forward-looking statements and risk factors, notably around the proposed sale of Park Holidays, liquidity, refinancing, interest rates, and macroeconomic conditions.
• · The presentation will be posted on Sun Communities' website at www.suninc.com/investor-relations.

01-06-2026

Community Health Systems Inc. completed the sale of four Arkansas hospitals and associated outpatient centers to Freeman-Oak Hill Health System for $110 million in cash on June 1, 2026. The transaction resulted in a pro forma net loss on sale of $48 million after tax, and the company recorded a $55 million pre-tax loss. Pro forma adjustments show the divested facilities contributed approximately $111 million in net operating revenues for Q1 2026 and $415 million for FY 2025, representing about 3.7% and 3.3% of total revenues, respectively.

• · The divested facilities' operations do not meet the definition of discontinued operations under ASC 205.
• · Pro forma adjustments exclude certain general corporate overhead costs previously allocated to the Facilities that will continue post-closing.
• · The pro forma net loss on sale of $48 million is after a $7 million income tax benefit.
• · For FY 2025, pro forma net income attributable to CHS stockholders decreased from $509 million to $472 million, and diluted EPS decreased from $3.77 to $3.50.
• · For Q1 2026, pro forma net loss attributable to CHS stockholders remained unchanged at $58 million, and diluted EPS remained at $(0.43).
• · The company's total assets decreased by $115 million on a pro forma basis, from $13,180 million to $13,065 million as of March 31, 2026.
• · Stockholders' deficit increased by $48 million on a pro forma basis, from $1,225 million to $1,273 million.

01-06-2026

Immuneering Corp announced updated Phase 2a data for atebimetinib in combination with mGnP in first-line pancreatic cancer, showing a median overall survival of 17.3 months in 55 patients (320 mg ITT population) versus 8.5 months for standard of care, with a median follow-up of 11.6 months. The drug was generally well tolerated, with Grade ≥3 adverse events including anemia (16%) and neutropenia (18%), and no Grade 5 events. However, the data are from a non-randomized trial without head-to-head comparison, and the company expects to start a pivotal Phase 3 trial in mid-2026 with topline data in mid-2028.

• · Median follow-up time was 11.6 months as of the cutoff date.
• · Grade ≥3 TEAEs in <10% of patients included Rash (5%), Fatigue (2%), Vomiting (2%), and Oedema Peripheral (2%).
• · No Grade 5 TEAEs were observed and no new safety signals were identified.
• · First patient in pivotal Phase 3 trial (MAPKeeper 301) expected in mid-2026 with topline data in mid-2028.
• · First patient in atebimetinib + Libtayo trial for NSCLC expected in H2 2026 with preliminary data in late-2027.
• · Additional preclinical data for atebimetinib + anti-PD-1 in NSCLC expected in Q4 2026.
• · IND-enabling studies for next Deep Cyclic Inhibition candidate expected to begin in mid-2027.

01-06-2026

Optimum Communications (OPTU) has launched a major capital structure repositioning by forming a new unrestricted subsidiary (Unsub Topco) to hold its Optimum East Cable business and 50.01% stake in Lightpath, insulating these assets from the $21.8 billion debt burden at its subsidiary CSC Holdings, of which $6.2 billion matures in 2027. The new subsidiary raised $500M through a $300M private placement of preferred units to institutional investors and a $200M exchange of preferred units for Optimum stock held by controlling stockholder Next Alt S.à r.l. at $2.50/share. Concurrently, a cash tender offer for up to $300M of Optimum common stock at $2.50/share has commenced. While these transactions aim to protect stakeholder value and facilitate consensual debt restructuring negotiations, the company faces a potential multi-billion-dollar tax liability exceeding $4 billion if a restructuring triggers a deconsolidation event, and the CSC Holdings debt maturity cliff in 2027 presents significant refinancing risk.

• · Co-Op Group holds approximately 99% of CSC Holdings Debt and has a Cooperation Agreement that prevents individual restructuring deals, severely limiting traditional refinancing options.
• · Unsub Topco structure was implemented in compliance with existing CSC Holdings debt documents and does not impact day-to-day operations, employees, management team, or board composition.
• · If significantly fewer shares are tendered than the $300M maximum, Unsub Topco plans to conduct a registered public exchange offering preferred units on similar economic terms.
• · Optimum is not a guarantor or obligor under CSC Holdings Debt — it is a holding company.
• · Advisors: Evercore (placement agent), Altman Solon LP (industry consultant), White & Case and Quinn Emanuel (legal counsel).

01-06-2026

Aditxt, Inc. (ADTX) appointed Jeffrey M. Busch as Interim CEO effective May 31, 2026, replacing founder Amro Albanna who resigned as CEO and board member. Mr. Busch previously founded a NYSE-listed healthcare REIT (Global Medical REIT/GMRE) that he built to over $1 billion in enterprise value while delivering ~8.5% average dividend yield to shareholders. The company plans to accelerate commercialization of its Ignite Proteomics precision oncology diagnostics platform under the new leadership. While the press release is optimistic about Busch's background and the strategic priorities, the filing does not disclose any financial figures for Aditxt itself, nor does it address the company's current liquidity, revenue trajectory, or going concern risks — significant uncertainties typical for a small-cap life sciences company with no disclosed dividend policy and a volatile stock (Nasdaq: ADTX).

• · Aditxt does not currently have a dividend policy and has no current plan or intention to declare cash dividends — the 8.5% dividend yield reference relates solely to Busch's prior role at GMRE, not Aditxt.
• · Busch has served as CEO of Ignite Proteomics since March 2026 and will continue both roles.
• · The outgoing CEO Amro Albanna resigned as CEO, from the board, and from all subsidiary positions — he co-founded Aditxt and led the company through its public listing and acquisition strategy.
• · Aditxt's strategic priorities under new leadership are: patients first, revenue-driven innovation, stakeholder responsibility, and capital market engagement.
• · Ignite Proteomics holds a Medicare PLA code for its RPPA-based precision oncology tests and has clinical collaborations with Dana-Farber Cancer Institute and Vanderbilt University Medical Center.
• · The press release provides no current financial data for Aditxt (no revenue, cash balance, debt, or operating metrics).

01-06-2026

Dime Community Bancshares, Inc. filed a Certificate of Amendment to change its corporate name to 'Dime Commercial Bancshares, Inc.' The amendment was authorized by the board of directors and a majority shareholder vote. The name change reflects a strategic shift from a community banking focus to a commercial banking identity.

• · The original incorporation date was September 13, 1998.
• · The company was originally formed as Bridge Bancorp, Inc.
• · The amendment was filed under Section 805 of the New York Business Corporation Law.
• · The filing fee for the certificate was $60.